EC Number   |
General Information |
Reference |
|---|
   2.7.7.48 | drug target |
analysis of the enzyme as a potential therapeutic drug target using a computational approach. Targeting the RdRpactive sites, ASP760 and ASP761, by antiviral drugs could be a potential therapeutic option for inhibition of coronavirus RdRp, and thus viral replication. Target-based virtual screening and molecular docking results show that the antiviral Galidesivir and its structurally similar compounds show promise against SARS-CoV-2. CID123624208 and CID11687749 may be considered for in vitro and in vivo clinical trials |
759688 |
| 2.7.7.48 | drug target |
cryo-electron microscopy structure of the SARS-CoV-2 RNA-dependent RNA polymerase provides insights into the mechanism of viral RNA replication and a rational template for drug design to combat the viral infection |
760198 |
| 2.7.7.48 | drug target |
drug target for COVID-19 |
758739 |
| 2.7.7.48 | drug target |
FDA approved library of drugs are docked against the active site of the enzyme (RdRp) using Schrodinger's computer-aided drug discovery tools for in silico drug-repurposing. In molecular dynamics simulations, pitavastatin, ridogrel and rosoxacin displayed superior binding with the active site through Arg555 and Mg2+ |
759164 |
| 2.7.7.48 | drug target |
important target for design of antiviral drugs against 2019-nCoV |
754405 |
| 2.7.7.48 | drug target |
inhibition of the viral RNA-dependent RNA polymerase (RdRp) to resolve chronic infection is a useful therapeutic strategy against Hepatitis C virus |
759516 |
| 2.7.7.48 | drug target |
RNA-dependent RNA polymerase inhibitors are prospective therapeutics against SARS-CoV-2 |
759616 |
| 2.7.7.48 | drug target |
SARS-CoV-2 polymerase is a key drug target for COVID-19 |
759672 |
| 2.7.7.48 | drug target |
search for drugs that target RNA-dependent RNA polymerase (RdRp) by in silico screening of the U.S. Food and Drug Administration approved drug library. Well-tolerated and widely used drugs are selected for molecular dynamics simulations to evaluate drug-protein interactions and their persistence under physiological conditions. Eltrombopag, tipranavir, ergotamine, and conivaptan bind to the enzyme with high binding free energies |
759517 |
| 2.7.7.48 | drug target |
since virally-encoded RNA-dependent RNA polymerases of RNA viruses synthesizes new genomes in the infected host they are prime targets for antiviral therapy |
759501 |
